Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The Company’s lead candidates under development are the oral gamma secretase inhibitor, AL102, for desmoid tumors, and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). AL102 has received Fast Track Designation from the U.S. FDA and is currently in the Phase 3 segment of a pivotal study for patients with desmoid tumors (RINGSIDE). For more information, visit www.ayalapharma.com.
Company profile
Ticker
ADXS
Exchange
Website
CEO
Kenneth Berlin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Advaxis, Inc., GREAT EXPECTATIONS & ASSOCIATES INC
SEC CIK
Corporate docs
IRS number
841521955
ADXS stock data
Latest filings (excl ownership)
8-K/A
Financial Statements and Exhibits
19 Apr 24
10-K
2023 FY
Annual report
16 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Apr 24
Latest ownership filings
4
Change in insider ownership
6 Mar 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
4
Change in insider ownership
12 Feb 24
SC 13D/A
Israel Biotech Fund I, L.P.
12 Feb 24
SC 13G/A
Schindel Yair Chaim
12 Feb 24
4
Change in insider ownership
21 Nov 23
SC 13D/A
Israel Biotech Fund I, L.P.
21 Nov 23
3
Yuval Cabilly
8 Nov 23
3/A
Roy Golan
3 Nov 23
3/A
Pini Orbach
3 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Oct 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Oct 22 | Oct 21 | Oct 20 | Oct 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 14.12 mm | 14.12 mm | 14.12 mm | 14.12 mm | 14.12 mm | 14.12 mm |
Cash burn (monthly) | (no burn) | 1.17 mm | 2.42 mm | 2.71 mm | 2.33 mm | 2.11 mm |
Cash used (since last report) | n/a | 7.94 mm | 16.47 mm | 18.43 mm | 15.80 mm | 14.30 mm |
Cash remaining | n/a | 6.18 mm | -2.34 mm | -4.31 mm | -1.68 mm | -172.67 k |
Runway (months of cash) | n/a | 5.3 | -1.0 | -1.6 | -0.7 | -0.1 |
Institutional ownership, Q2 2023
6.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 1 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 2.16 mm |
Total shares | 2.56 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 2.00 mm | $697.00 k |
Yair Chaim Schindel | 560.60 k | $1.46 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Israel Biotech Fund I | Warrants Common Stock | Option exercise | Acquire M | Yes | No | 0.4 | 2,250,000 | 900.00 k | 13,462,500 |
1 Mar 24 | Israel Biotech Fund I | Warrants Common Stock | Option exercise | Acquire M | Yes | No | 0.4 | 2,250,000 | 900.00 k | 7,837,500 |
1 Mar 24 | Israel Biotech Fund I | Convertible Promissory Note Common Stock | Option exercise | Acquire M | Yes | No | 0.4 | 1,500,000 | 600.00 k | 11,212,500 |
1 Mar 24 | Israel Biotech Fund I | Convertible Promissory Note Common Stock | Option exercise | Acquire M | Yes | No | 0.4 | 1,500,000 | 600.00 k | 5,587,500 |
1 Mar 24 | Israel Biotech Fund I | Rights Common Stock | Option exercise | Dispose M | Yes | No | 0.4 | 3,750,000 | 1.50 mm | 9,712,500 |
1 Mar 24 | Israel Biotech Fund I | Rights Common Stock | Option exercise | Dispose M | Yes | No | 0.4 | 3,750,000 | 1.50 mm | 4,087,500 |
7 Feb 24 | Israel Biotech Fund I | Common Stock, par value $0.001 per share | Payment of exercise | Dispose F | Yes | No | 1.2465 | 2,586,905 | 3.22 mm | 25,130,903 |
7 Feb 24 | Israel Biotech Fund I | Common Stock, par value $0.001 per share | Option exercise | Acquire M | Yes | No | 0.4 | 8,062,500 | 3.23 mm | 27,717,808 |
7 Feb 24 | Israel Biotech Fund I | Common Stock, par value $0.001 per share | Payment of exercise | Dispose F | Yes | No | 1.2465 | 2,707,581 | 3.37 mm | 20,661,639 |
7 Feb 24 | Israel Biotech Fund I | Common Stock, par value $0.001 per share | Option exercise | Acquire M | Yes | No | 0.4 | 8,437,500 | 3.38 mm | 23,369,220 |